Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
No DFS Benefit With Adjuvant Durvalumab in Early NSCLC
Adjuvant durvalumab (Imfinzi) provided no significant improvement in disease-free survival compared with placebo following resection in patients with early-stage non-small cell lung cancer (NSCLC), according to findings from the phase 3 BR.31 trial. In the overall population, median disease-free survival…
English